PBH vs. RARE, HCM, AXSM, BHVN, XENE, SMMT, IDYA, CRNX, JANX, and ARWR Should you be buying Prestige Consumer Healthcare stock or one of its competitors? The main competitors of Prestige Consumer Healthcare include Ultragenyx Pharmaceutical (RARE), HUTCHMED (HCM), Axsome Therapeutics (AXSM), Biohaven (BHVN), Xenon Pharmaceuticals (XENE), Summit Therapeutics (SMMT), IDEAYA Biosciences (IDYA), Crinetics Pharmaceuticals (CRNX), Janux Therapeutics (JANX), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical preparations" industry.
Ultragenyx Pharmaceutical (NASDAQ:RARE ) and Prestige Consumer Healthcare (NYSE:PBH ) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends.
Ultragenyx Pharmaceutical has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.
In the previous week, Prestige Consumer Healthcare had 27 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 30 mentions for Prestige Consumer Healthcare and 3 mentions for Ultragenyx Pharmaceutical. Prestige Consumer Healthcare's average media sentiment score of 1.01 beat Ultragenyx Pharmaceutical's score of 0.43 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.
Prestige Consumer Healthcare has a net margin of 18.60% compared to Prestige Consumer Healthcare's net margin of -138.58%. Ultragenyx Pharmaceutical's return on equity of 13.48% beat Prestige Consumer Healthcare's return on equity.
Ultragenyx Pharmaceutical currently has a consensus target price of $87.85, indicating a potential upside of 109.81%. Prestige Consumer Healthcare has a consensus target price of $95.00, indicating a potential upside of 46.95%. Given Prestige Consumer Healthcare's stronger consensus rating and higher probable upside, research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Prestige Consumer Healthcare.
97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 6.8% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 1.6% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Ultragenyx Pharmaceutical received 322 more outperform votes than Prestige Consumer Healthcare when rated by MarketBeat users. Likewise, 77.11% of users gave Ultragenyx Pharmaceutical an outperform vote while only 70.61% of users gave Prestige Consumer Healthcare an outperform vote.
Prestige Consumer Healthcare has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.
Summary Ultragenyx Pharmaceutical and Prestige Consumer Healthcare tied by winning 9 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding PBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Prestige Consumer Healthcare Competitors List
Related Companies and Tools
